GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.26 Million EUR | -50.93% |
| 2022 | 2.58 Million EUR | -51.06% |
| 2021 | 5.27 Million EUR | 20.07% |
| 2020 | 4.39 Million EUR | 527.71% |
| 2019 | 700 Thousand EUR | -83.89% |
| 2018 | 4.34 Million EUR | 17.4% |
| 2017 | 3.7 Million EUR | 23.36% |
| 2016 | 3 Million EUR | -15.7% |
| 2015 | 3.55 Million EUR | 222.85% |
| 2014 | 1.1 Million EUR | 21.38% |
| 2013 | 908.44 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 864 Thousand EUR | 596.77% |
| 2024 Q2 | 864 Thousand EUR | 0.0% |
| 2023 Q3 | 124 Thousand EUR | -92.0% |
| 2023 Q1 | 1.35 Million EUR | 342.35% |
| 2023 Q4 | 124 Thousand EUR | 0.0% |
| 2023 FY | 1.26 Million EUR | -50.93% |
| 2023 Q2 | 1.55 Million EUR | 14.14% |
| 2022 Q4 | 307 Thousand EUR | 0.0% |
| 2022 Q3 | 307 Thousand EUR | -89.96% |
| 2022 Q1 | 2.12 Million EUR | 413.41% |
| 2022 Q2 | 3.05 Million EUR | 43.87% |
| 2022 FY | 2.58 Million EUR | -51.06% |
| 2021 FY | 5.27 Million EUR | 20.07% |
| 2021 Q2 | 5.57 Million EUR | 61.9% |
| 2021 Q4 | 414 Thousand EUR | 0.0% |
| 2021 Q1 | 3.44 Million EUR | -6.86% |
| 2021 Q3 | 414 Thousand EUR | -92.57% |
| 2020 Q2 | 700 Thousand EUR | -57.29% |
| 2020 Q3 | 2.08 Million EUR | 197.29% |
| 2020 Q4 | 3.69 Million EUR | 77.51% |
| 2020 FY | 4.39 Million EUR | 527.71% |
| 2020 Q1 | 1.63 Million EUR | 134.14% |
| 2019 Q3 | 1.22 Million EUR | -0.89% |
| 2019 Q2 | 1.23 Million EUR | 0.0% |
| 2019 Q1 | 1.23 Million EUR | 6.34% |
| 2019 FY | 700 Thousand EUR | -83.89% |
| 2019 Q4 | 700 Thousand EUR | -42.72% |
| 2018 Q1 | 1.01 Million EUR | 18.26% |
| 2018 Q3 | 1.15 Million EUR | 14.41% |
| 2018 Q4 | 1.15 Million EUR | 0.0% |
| 2018 FY | 4.34 Million EUR | 17.4% |
| 2018 Q2 | 1.01 Million EUR | 0.0% |
| 2017 Q4 | 857 Thousand EUR | 0.0% |
| 2017 Q1 | 994 Thousand EUR | 76.4% |
| 2017 FY | 3.7 Million EUR | 23.36% |
| 2017 Q2 | 994 Thousand EUR | 0.0% |
| 2017 Q3 | 857 Thousand EUR | -13.78% |
| 2016 Q1 | 937 Thousand EUR | 6.31% |
| 2016 Q3 | 563.5 Thousand EUR | -39.86% |
| 2016 Q2 | 937 Thousand EUR | 0.0% |
| 2016 Q4 | 563.5 Thousand EUR | 0.0% |
| 2016 FY | 3 Million EUR | -15.7% |
| 2015 Q3 | 881.39 Thousand EUR | -1.91% |
| 2015 Q4 | 881.39 Thousand EUR | 0.0% |
| 2015 FY | 3.55 Million EUR | 222.85% |
| 2015 Q2 | 898.6 Thousand EUR | 0.0% |
| 2015 Q1 | 898.6 Thousand EUR | 338.55% |
| 2014 Q4 | 204.9 Thousand EUR | 0.0% |
| 2014 FY | 1.1 Million EUR | 21.38% |
| 2014 Q1 | 346.44 Thousand EUR | 0.0% |
| 2014 Q3 | 204.9 Thousand EUR | -40.85% |
| 2014 Q2 | 346.44 Thousand EUR | 0.0% |
| 2013 FY | 908.44 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 72.694% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 72.582% |
| Adocia SA | 2.15 Million EUR | 41.07% |
| Aelis Farma SA | 9.05 Million EUR | 86.006% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 59.791% |
| genOway Société anonyme | 20.04 Million EUR | 93.68% |
| IntegraGen SA | 12.53 Million EUR | 89.894% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -322.285% |
| Neovacs S.A. | 533.41 Thousand EUR | -137.527% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 24.651% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -6300.283% |
| Sensorion SA | 4.74 Million EUR | 73.287% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -327.562% |
| TME Pharma N.V. | 17 Thousand EUR | -7352.941% |
| Valbiotis SA | 4.73 Million EUR | 73.231% |
| TheraVet SA | 1.07 Million EUR | -17.526% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 29.611% |
| argenx SE | 1.13 Billion EUR | 99.888% |
| BioSenic S.A. | 543 Thousand EUR | -133.333% |
| Celyad Oncology SA | 102 Thousand EUR | -1142.157% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.471% |
| Genfit S.A. | 28.56 Million EUR | 95.565% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 39.291% |
| Innate Pharma S.A. | 51.9 Million EUR | 97.559% |
| Inventiva S.A. | 17.47 Million EUR | 92.75% |
| MaaT Pharma SA | 2.22 Million EUR | 43.133% |
| MedinCell S.A. | 9.16 Million EUR | 86.168% |
| Nanobiotix S.A. | 30.05 Million EUR | 95.785% |
| Onward Medical N.V. | 532 Thousand EUR | -138.158% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 91.072% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 43.107% |
| Oxurion NV | 263 Thousand EUR | -381.749% |
| Pharming Group N.V. | 245.31 Million EUR | 99.484% |
| Poxel S.A. | 1.98 Million EUR | 36.042% |
| Transgene SA | 1.18 Million EUR | -7.01% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.976% |
| Valneva SE | 153.71 Million EUR | 99.176% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 135.0% |